Medical tech firm Becton Dickinson's Q4 revenue up 8.3%, adjusted EPS beats estimates

Becton Dickinson and

06/11/2025 11:39

Overview

Becton Dickinson Q4 revenue grows 8.3%, adjusted EPS beats analyst expectations

Company returned $2.2 bln to shareholders in FY25 through dividends and share repurchases

BD issues FY26 guidance with adjusted EPS expected between $14.75 and $15.05

Outlook

Company expects FY26 adjusted diluted EPS between $14.75 and $15.05

BD anticipates low single-digit revenue growth for FY26

Result Drivers

BD MEDICAL GROWTH - Strong performance in Advanced Patient Monitoring, aided by acquisition from Edwards Lifesciences

DIAGNOSTIC SOLUTIONS RECOVERY - Diagnostic Solutions unit returned to positive growth with improved product utilization

INTERVENTIONAL GROWTH - Urology and Critical Care unit saw double-digit growth, driven by PureWick franchise

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$3.96
$3.92 (12 Analysts)
Q4 EPS
$1.72


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Becton Dickinson and Co is $200.96, about 12.2% above its November 5 closing price of $176.39

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPnc6QcBta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)